Entia Biosciences (ERGO) Stock Statistics & Valuation Metrics
Total Valuation
Entia Biosciences has a market cap or net worth of $33.66K. The enterprise value is $980.05B.
- Market Cap
- $33.66K
- Enterprise Value
- $980.05B
Share Statistics
Entia Biosciences has 33,661,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 33,661,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.30%
Financial Efficiency
Entia Biosciences’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 0.00%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- 0
- Profits Per Employee
- 0
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Entia Biosciences is -0.01. Entia Biosciences’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.04
- PB Ratio
- -0.00
- Price to FCF
- -0.01
- Price to Operating Cash Flow
- -0.01
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Entia Biosciences had revenue of 0 and earned 0 in profits. Earnings per share was 0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- 0
- Pretax Income
- 0
- Net Income
- 0
- EBITDA
- 0
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was -715.10K and capital expenditures -7,117, giving a free cash flow of -722.22K billion.
- Operating Cash Flow
- -715.10K
- Free Cash Flow
- -722.22K
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Entia Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7152.06%
- Earnings Yield
- -17446.65%
Stock Price Statistics
- Beta
- -68.62
- 52-Week Price Change
- 300.00%
- 50-Day Moving Average
- 0.04
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Entia Biosciences as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.00
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Entia Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Entia Biosciences EV to EBITDA ratio is -0.76, with an EV/FCF ratio of -1.36.
- EV to Sales
- 3.69
- EV to EBITDA
- -0.76
- EV to Free Cash Flow
- -1.36
- EV to Operating Cash Flow
- -1.37
Margins
Gross margin is 65.53%, with operating margin of -439.75%, and net profit margin of -554.75%.
- Gross Margin
- 65.53%
- Operating Margin
- -439.75%
- Pretax Margin
- -525.79%
- Net Profit Margin
- -554.75%
- EBITDA Margin
- -487.66%
- EBIT Margin
- -494.33%
Analyst Forecast
The average price target for Entia Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―